Xeris Biopharma Holdings, Inc. (XERS)

Xeris Biopharma Holdings Stock Forecast

Stock Price Forecast

The 6 analysts that cover Xeris Biopharma Holdings stock have a consensus rating of "Buy" and an average price target of $10.83, which forecasts a 93.57% increase in the stock price over the next year. The lowest target is $8.00 and the highest is $18.

Price Target: $10.83 (+93.57%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$8.00	$10.83	$10	$18
Change	+42.98%	+93.57%	+78.73%	+221.72%

Analyst Ratings

The average analyst rating for Xeris Biopharma Holdings stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '25	Nov '25	Dec '25	Jan '26	Feb '26	Mar '26
Strong Buy	4	4	3	3	3	2
Buy	2	2	3	3	3	3
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	7	7	7	7	7	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Brandon Folkes HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $10	Strong Buy	Reiterates	$10	+78.73%	Mar 2, 2026
Brandon Folkes HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $10	Strong Buy	Reiterates	$10	+78.73%	Jan 9, 2026
Glen Santangelo Barclays	Barclays	Buy Initiates $9	Buy	Initiates	$9	+60.86%	Dec 9, 2025
Leland Gershell Oppenheimer	Oppenheimer	Buy Maintains $18	Buy	Maintains	$18	+221.72%	Nov 7, 2025
Brandon Folkes HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $10	Strong Buy	Maintains	$10	+78.73%	Nov 7, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

375.46M

Increased by 28.65%

from 291.85M

Revenue Next Year

444.27M

Increased by 18.33%

from 375.46M

EPS This Year

0.19

Increased by 5,672.68%

from 0.00

EPS Next Year

0.36

Increased by 96.14%

from 0.19

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	49.59M	110.25M	163.91M	203.07M	291.85M	375.46M	444.27M
Revenue Growth	142.67%	122.32%	48.68%	23.89%	43.72%	28.65%	18.33%
EPS	-1.55	-0.70	-0.45	-0.37	0.00	0.19	0.36
EPS Growth	-	-	-	-	-	5,672.68%	96.14%
Forward PE	-	-	-	-	-	30.22	15.41
No. Analysts	-	-	-	-	-	9	8

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028	2029	2030
High	453.9M	526.2M
Avg	375.5M	444.3M
Low	331.1M	382.5M

Revenue Growth

Revenue Growth	2026	2027	2028	2029	2030
High	55.5%	40.1%
Avg	28.7%	18.3%
Low	13.5%	1.9%

EPS Forecast

EPS	2026	2027
High	0.43	0.64
Avg	0.19	0.36
Low	-0.03	0.11

EPS Growth

EPS Growth	2026	2027
High	13,323.8%	246.0%
Avg	5,672.7%	96.1%
Low	-	-41.8%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.